EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron overload without the C282Y mutation in patients with epilepsy



Iron overload without the C282Y mutation in patients with epilepsy



Journal of Neurology, Neurosurgery, and Psychiatry 70(4): 551-553



To test the hypothesis that iron overload predisposes to epilepsy, transferrin saturation in 130 patients with epilepsy and sex and age matched 128 control subjects without epilepsy were studied. Mean transferrin saturation was significantly higher in the epilepsy group (39.9 (SD 19.6)%) than in the control group (29.1 (SD 14.9)%). Abnormally high transferrin saturations (men>60%, women>48%) were found in 10 patients with epilepsy but in only one subject without epilepsy. Antiepileptic drugs did not affect the transferrin saturation. Of the 11 with abnormally high transferrin saturation, two with epilepsy were heterozygotic for H63D in the haemochromatosis gene but no patient had the C282Y mutation. These results indicate that iron overload other than the C282Y mutation underlies epilepsy.

(PDF emailed within 0-6 h: $19.90)

Accession: 010885297

Download citation: RISBibTeXText

PMID: 11254788

DOI: 10.1136/jnnp.70.4.551



Related references

Multiorgan iron overload in patients without C282Y mutation. Gastroenterology 120(5 Supplement 1): A 565-A 566, April, 2001

HAMP promoter mutation nc.-153C>T in non p.C282Y homozygous patients with iron overload. Haematologica 95(4): 687-688, 2010

Gene-environment interaction in hereditary haemochromatosis Effect of excessive alcohol use on iron overload in patients homozygous for the C282Y mutation. European Journal of Human Genetics 10(Supplement 1): 184, 2002

Iron overload in compound and simple heterozygotes for the C282Y mutation. Blood 94(10 SUPPL 1 PART 1): 404a, Nov 15, 1999

The S65C mutation of HFE may contribute to iron overload in C282Y heterozygotes. Journal of Hepatology 32(Supplement 2): 135, 2000

Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. Journal of Hepatology 36(4): 474-479, 2002

Transplantation of a liver with the C282Y mutation into a recipient heterozygous for H63D results in iron overload. American Journal of the Medical Sciences 337(2): 138-142, 2009

Genetic predisposition to iron overload: prevalence and phenotypic expression of hemochromatosis-associated HFE-C282Y gene mutation. Scandinavian Journal of Clinical and Laboratory Investigation 66(2): 83-100, 2006

A previously undescribed frameshift deletion mutation of HFE (c.del277; G93fs) associated with hemochromatosis and iron overload in a C282Y heterozygote. Clinical Genetics 66(3): 214-216, 2004

HFE hemochromatosis: influence of dietary iron intake on the iron overload of C282Y homozygous patients. Annals of Hematology 94(7): 1225-1227, 2015

HLA-A3-B14 and the origin of the haemochromatosis C282Y mutation: founder effects and recombination events during 12 generations in a Scandinavian family with major iron overload. European Journal of Haematology 84(2): 145-153, 2010

1% of adults homozygous for the C282Y mutation of the HFE gene have been clinically diagnosed with iron overload Evidence from the South Wales haemochromatosis study. Gut 50(Supplement 2): A113, April, 2002

Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut 51(5): 723-730, 2002

Absence of overt iron overload in two individuals compound heterozygotes for a 22 base pair deletion of exon 2 and the C282Y missense mutation of the HFE gene. Clinical Genetics 63(2): 163-165, 2003

Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 100(3): 1075-1077, 2002